Drug Trial Radar · NCT03363373
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
Apr 3, 2018
Primary completion
Jun 30, 2026
Study completion Apr 2028
Sponsor
- Lead sponsor
- Y-mAbs TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Conditions
- Neuroblastoma
Interventions
GM-CSF + NaxitamabBiological
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate during Naxitamab treatmentTime frame: 101 weeks
Locations
20 sites in 9 countries. Site status is shown where the registry gives one.
Riley Hospital for Children
Indianapolis, Indiana
Memorial Sloan Kettering Cancer Center
New York, New York
The Hospital for Sick Children
Toronto, Canada
Rigshospitalet
Copenhagen, Denmark
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Johannes Gutenberg-Universität
Mainz, Germany
University Hospital Regensburg
Regensburg, Germany
Hong Kong Children's Hospital
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Tata Memorial Centre
Mumbai, India
Ospedale Pediatrico Bambino Gesù
Rome, Italy
Giannina Gaslini Hospital
Genoa, Genoa, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milan, Italy
Hospital Sant Joan de Déu
Barcelona, Spain
Hospital Infantil Universitario Niño Jesús
Madrid, Spain
Hospital Universitario Virgen Del Rocío
Seville, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
The Royal Glasgow Children's Hospital
Glasgow, United Kingdom
Leeds General Infirmary
Leeds, United Kingdom
University Hospital Southampton
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.